直接口服抗凝药在老年房颤患者中的临床应用指引：平衡卒中预防与出血风险的药学监护策略 |
| 黄露雯 |
| 中国澳门卫生中心局药房，澳门，999078 |
摘要：目的：随着直接口服抗凝药（DOACs）在非瓣膜型房颤卒中预防中的广泛应用，老年患者因其特殊的生理病理特征，成为抗凝治疗中风险最高、管理最复杂的群体。本文旨在基于最新循证证据与临床指南，系统构建针对老年房颤患者的DOACs临床用药指引与药学监护策略。方法：系统性检索并分析近五年PubMed、EMBASE、CochraneLibrary、中国知网及万方数据库中关于DOACs在老年房颤患者中应用的随机对照试验、亚组分析、真实世界研究、Meta分析及相关指南。结果：共纳入50篇关键文献。证据表明，在老年（尤其≥75岁）及高龄（≥80岁）房颤患者中，DOACs在预防卒中/体循环栓塞方面的疗效不劣于或优于华法林，且能显著降低颅内出血这一致命性风险。然而，老年患者年龄相关肾功能减退、低体重、多病共存及多重用药问题普遍，显著增加了DOACs的出血风险和管理难度。成功的抗凝管理依赖于贯穿治疗全程的精细化药学监护：治疗前需综合评估CHA?DS?-VASc与HAS-BLED评分，并依据肾功能、体重及药物相互作用精确选择药物与剂量；治疗中需动态监测肾功能与出血迹象，并有效管理与P-糖蛋白/CYP3A4抑制剂的相互作用；出血事件发生时，需根据分级采取相应措施，并了解特定逆转剂的应用。结论：DOACs为老年房颤患者提供了更安全的抗凝选择，但其获益最大化依赖于“个体化、动态化、全程化”的药学监护。临床医师与药师应协同工作，遵循以患者为中心的用药指引，在有效预防卒中的同时，将出血风险降至最低。
关健词：直接口服抗凝药；心房颤动；老年患者；非瓣膜型房颤；卒中预防；出血风险；药学监护；用药指引
|
|
Clinical Application Guidance for Direct Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Pharmaceutical Monitoring Strategy for Balancing Stroke Prevention and Bleeding Risk |
Luwen Huang
Pharmacy Department,Macau Health Bureau,Macau China，999078
|
Abstract：Objective：With the widespread use of direct oral anticoagulants （DOACs） for stroke prevention in non-valvular atrial fibrillation （NVAF）,elderly patients have become the highest-risk and most complex group for anticoagulant management due to their specific pathophysiological characteristics. This review aims to systematically develop clinical medication guidance and pharmaceutical monitoring strategies for DOACs in elderly AF patients based on the latest evidence and clinical guidelines. Methods：A systematic search and analysis of key literature from the past five years in databases including PubMed,EMBASE,the Cochrane Library,CNKI,and Wanfang Data were conducted,focusing on randomized controlled trials,subgroup analyses,real-world studies,meta-analyses,and relevant guidelines concerning the use of DOACs in elderly AF patients. Results：A total of 50 key articles were included. Evidence indicates that in elderly （especially ≥75 years） and very elderly （≥80 years） AF patients,DOACs are non-inferior or superior to warfarin in preventing stroke/systemic embolism while significantly reducing the risk of intracranial hemorrhage. However,age-related renal impairment,low body weight,comorbidities,and polypharmacy prevalent in this population significantly increase the bleeding risk and management complexity of DOACs. Successful anticoagulation management relies on meticulous pharmaceutical monitoring throughout the treatment course: pre-treatment requires comprehensive assessment using CHA?DS?-VASc and HAS-BLED scores,and precise drug/dose selection based on renal function,weight,and drug interactions； during treatment,dynamic monitoring of renal function and bleeding signs is essential,along with effective management of interactions with P-gp/CYP3A4 inhibitors； when bleeding occurs,graded management strategies and knowledge of specific reversal agents are required. Conclusion：DOACs offer a safer anticoagulation option for elderly AF patients,but maximizing their benefit depends on "individualized,dynamic,and comprehensive" pharmaceutical monitoring. Clinicians and pharmacists should collaborate,adhering to patient-centered medication guidance to effectively prevent stroke while minimizing bleeding risk.
Keywords : Direct Oral Anticoagulants；Atrial Fibrillation；Elderly Patients；Non-Valvular Atrial Fibrillation；Stroke Prevention；Bleeding Risk；Pharmaceutical Monitoring； Medication Guidance
参考文献
[1]HindricksG,etal.2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillationdevelopedincollaborationwiththeEuropeanAssociationforCardio-ThoracicSurgery.EurHeartJ.2021；42（5）:373-498.
[2]JanuaryCT,etal.2019AHA/ACC/HRSFocusedUpdateofthe2014AHA/ACC/HRSGuidelinefortheManagementofPatientsWithAtrialFibrillation.JAmCollCardiol.2019；74（1）:104-132.
[3]SteffelJ,etal.The2021EuropeanHeartRhythmAssociationPracticalGuideontheUseofNon-VitaminKAntagonistOralAnticoagulantsinPatientswithAtrialFibrillation.Europace.2021；23（10）:1612-1676.
[4]ChaoTF,etal.Strokepreventioninatrialfibrillation:AscientificstatementofJACC:Asia.JACC:Asia.2022；2（4）:395-411.
[5]中华医学会心血管病学分会，中国老年学学会心脑血管病专业委员会.老年非瓣膜性心房颤动诊治中国专家建议（2016）.中华心血管病杂志，2016,44（12）:987-993.
[6]DiBiaseL,etal.Directoralanticoagulantsforstrokepreventioninelderlypatientswithatrialfibrillation:asystematicreviewandmeta-analysis.JAmHeartAssoc.2021；10（15）:e021209.
[7]国家卫生健康委员会合理用药专家委员会.新型口服抗凝药临床应用中国专家共识（2023版）.中国医学前沿杂志（电子版）,2023,15（7）:1-28.
[8]RossiA,etal.Real-worldeffectivenessandsafetyofdirectoralanticoagulantsversuswarfarininveryelderlypatients（≥75years）withatrialfibrillation:Amultinationalcohortstudy.ThrombRes.2023；226:108765.
[9]WangY,etal.Pharmacogenomics-guideddoseadjustmentofdirectoralanticoagulantsinelderlypatientswithatrialfibrillation:Apilotstudy.PharmacogenomicsJ.2024；24（2）:189-196.
|
|
|
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
|
|
